Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Shengbai Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3918-0980; OpenAlex author ID A5070618787. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2022: 6 papers · 2023: 3 papers · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 14

  1. The bile acid TUDCA promotes chemoresistance and predicts survival through MAPK signaling in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00018-026-06210-4↗
  2. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218684↗
  3. The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03644-2↗
  4. Correction to: The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03739-w↗
  5. The Role of Bile Acids in Pancreatic Cancer. Co-author DOI 10.2174/0115680096281168231215060301↗
  6. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  7. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  8. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. Co-author DOI 10.1049/syb2.12068↗
  9. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
  10. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Co-author DOI 10.1186/s12935-022-02807-4↗
  11. Cuproptosis-related lncRNAs are correlated with metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients Co-author DOI 10.21203/rs.3.rs-1645540/v1↗
  12. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  13. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
  14. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3390/ijms24010156↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 12 shared papers, 2022–2026 · strength 2.15
  2. Xiaofei Zhang · 10 shared papers, 2022–2024 · strength 1.52
  3. Tiebo Mao · 9 shared papers, 2022–2024 · strength 1.35
  4. Weiyu Ge · 9 shared papers, 2022–2023 · strength 1.32
  5. Liwei Wang · 5 shared papers, 2022–2026 · strength 0.91
  6. Liwei Wang · 5 shared papers, 2022–2024 · strength 0.84
  7. Yanling Wang · 4 shared papers, 2022–2026 · strength 0.83
  8. Yanling Wang · 5 shared papers, 2022–2024 · strength 0.81
  9. Liwei Wang · 3 shared papers, 2022–2024 · strength 0.50
  10. Qing Xia · 2 shared papers, 2024 · strength 0.40
  11. Wenxin Lu · 2 shared papers, 2024 · strength 0.40
  12. Jiayu Yao · 3 shared papers, 2022 · strength 0.39
  13. Shumin Li · 2 shared papers, 2022–2023 · strength 0.30
  14. Yanling Wang · 1 shared paper, 2026 · strength 0.30
  15. Liwei Wang · 1 shared paper, 2026 · strength 0.30
  16. Yu Wang · 1 shared paper, 2024 · strength 0.20
  17. Yanling Wang · 1 shared paper, 2022 · strength 0.17
  18. Ming Quan · 1 shared paper, 2023 · strength 0.16
  19. Xiao Zhang · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.